COMP <GO>
UPC vs MRK // DIVIDEND YIELD & FCF PAYOUT SAFETY
Universe Pharmaceuticals Inc. (Class A) (NASDAQ) VS. Merck & Company Inc. (NYSE) • 15-METRIC TALLY: UPC 0
— MRK 8
▲ DIVIDEND YIELD & FCF PAYOUT SAFETY LEADER: MRK
LAST: $1.49 (-3.25%) • MKT CAP: $7.7M
dividend-safety
0.00%
LAST: $149.52 (+2.18%) • MKT CAP: $361.02B
dividend-safety
2.26%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (UPC VS. MRK)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | UPC | MRK | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | 35.30% | 74.80% | -39.50 | MRK | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | — | 20.70% | — | TIE | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 15.3x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | — | 3.42% | — | TIE | /fcf-yield <GO> |
| Operating Margin | -16.30% | 34.30% | -50.60 | MRK | /operating-margins <GO> |
| Net Profit Margin | -20.60% | 28.10% | -48.70 | MRK | /net-margins <GO> |
| Revenue Growth (YoY) | -22.40% | 1.30% | -23.70 | MRK | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety ACTIVE | 0.00% | 2.26% | -2.26 | MRK | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | — | 5.19 | — | TIE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 2/9 | 7/9 | -5.00 | MRK | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 23.3 | 51.7 | -28.40 | MRK | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | — | 0.92 | — | TIE | /macro-sensitivity <GO> |
| Forward P/E Multiple | — | 18.4x | — | TIE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $7.7M | $361.02B | -$361.01B | MRK | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | UPC REV | MRK REV | UPC GROSS % | MRK GROSS % | UPC FCF | MRK FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $17.86B | $65.01B | 35.3% | 74.8% | -$5.32B | $12.36B |
| FY 2024 | $23.02B | $64.17B | 26.4% | 76.3% | -$9.72B | $18.10B |
| FY 2023 | $32.31B | $60.12B | — | — | $1.12B | $10.30B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
UPC // BETA —
MRK // BETA 0.92